AK-A inhibitors have shown impressive pre-clinical anti-tumor activity [26] as an active single agent to treat r/r aggressive B-NHLs [27] and peripheral T-cell lymphomas (PTCL) [28]. This evidence concerns the gene NEUROG1 and neoplasm.